

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number
WO 02/053186 A2

- (51) International Patent Classification⁷: **A61K 47/00** (74) Agents: **RAYMOND, Robert, P. et al.**; Boehringer Ingelheim Corp., 900 Ridgebury Road, Ridgefield, CT 06877 (US).
- (21) International Application Number: **PCT/US02/00104**
- (22) International Filing Date: **4 January 2002 (04.01.2002)** (81) Designated States (*national*): **CA, JP, MX.**
- (25) Filing Language: **English** (84) Designated States (*regional*): **European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).**
- (26) Publication Language: **English**
- (30) Priority Data:
09/754,777 **5 January 2001 (05.01.2001)** **US** Published:
— *without international search report and to be republished upon receipt of that report*
- (71) Applicant: **ROXANE LABORATORIES, INC.**
[US/US]; 1809 Wilson Road, COLUMBUS, OH 43228 (US).
For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.
- (72) Inventors: **DEDHIYA, Mahendra**; 6360 Twonotch Court, Dublin, OH 43016 (US). **ECONOMOU, Julia**; 2574 Cowall Drive, Hilliard, OH 43026 (US).



WO 02/053186 A2

(54) Title: **FLUTICASONE SUSPENSION FORMULATION, SPRAY PATTERN METHOD, AND NASAL SPRAY APPARATUS**

(57) Abstract: **An aqueous pharmaceutical formulation suitable for use in a pump spray device, comprising (a) fluticasone propionate, (b) an antimicrobial preservative, (c) a surfactant, (d) a tonicity agent, and (e) a suspending agent; methods for using the aqueous pharmaceutical formulation, and suitable pump spray devices.**

10

**FLUTICASONE SUSPENSION FORMULATION,
SPRAY PATTERN METHOD, AND NASAL SPRAY APPARATUS**

Background of the Invention

5 Fluticasone propionate is the approved name for S-fluoromethyl-6a,9a-difluoro-11b-hydroxy-16a-methyl-17a-propionyloxy-3-oxandrosta-1,4-diene-17b-carbothioate, a corticosteroid known to exhibit topical antiinflammatory activity and described and claimed in Phillipps *et al.*, U.S. Patent No. 4,335,121. Fluticasone propionate is indicated for the management of the nasal symptoms of seasonal and perennial allergic and
10 nonallergic rhinitis in adults and pediatric patients. In addition, in the treatment of asthmatic conditions, it has been found to be effective to administer fluticasone propionate in the form of dry powders or aerosols containing small particles of the medicament, conventionally prepared by micronization. Conventionally, fluticasone propionate nasal spray has been administered by means of a metered dose nasal spray device and aerosols
15 have been administered by means of metered dose inhalers, which are designed to deliver a fixed unit dosage of medicament per actuation or "puff".

The spray pattern test is now a widely accepted *in vitro* test for nasal pump spray delivery systems for all such nasally-delivered pharmaceutical formulations. The spray pattern test
20 was developed to assure equivalent drug deposition patterns, resulting in equivalent delivery of the drug, for example, fluticasone propionate, to nasal site of action and equivalent systemic exposure or absorption. The spray pattern test also assists in establishing *in vitro* bioavailability of the product in accordance, for example, with the publication of the U.S. Food and Drug Administration's (FDA) Draft Guidance for
25 Industry: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Spray for Local Action (June 1999)(incorporated herein by reference in its entirety and hereinafter referred to as "FDA Draft Guidance"). In order to meet the FDA Draft Guidance, which may become mandatory for the approval of such products, it has therefore become important to administer nasal sprays in a controlled manner, such that the
30 nasal spray produced has a desired and reproducible shape.

Brief Summary of the Invention

- The invention includes a suspension formulation containing fluticasone propionate in a pharmaceutically acceptable vehicle for nasal administration. In one aspect of the present invention there is provided an aqueous pharmaceutical formulation suitable for use in a
- 5 pump spray device, comprising:
- (a) fluticasone propionate;
 - (b) an antimicrobial preservative;
 - (c) a surfactant;
 - (d) a tonicity agent; and
 - 10 (e) a suspending agent.

- In a preferred embodiment of the invention, the antimicrobial preservative is selected from the group consisting of: benzalkonium chloride, methylparaben, sodium benzoate, benzoic acid, phenyl ethyl alcohol, mixtures thereof, and the like. In another preferred embodiment
- 15 of the invention, the surfactant is selected from the group consisting of: Polysorbate 80 NF, polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene (4) sorbitan monolaurate, polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 20 sorbitan monostearate, polyoxyethylene (4) sorbitan monostearate, polyoxyethylene 20 sorbitan tristearate, polyoxyethylene (5) sorbitan monooleate, polyoxyethylene 20 sorbitan trioleate,
- 20 polyoxyethylene 20 sorbitan monoisostearate, sorbitan monooleate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan trilaurate, sorbitan trioleate, sorbitan tristearate, mixtures thereof, and the like. In yet another preferred embodiment of the invention, the tonicity agent is selected from the group consisting of: dextrose, lactose, sodium chloride, mixtures thereof, and the like. In a further preferred embodiment of the
- 25 invention, the suspending agent is selected from the group consisting of: microcrystalline cellulose, carboxymethylcellulose sodium NF, polyacrylic acid, magnesium aluminum silicate, xanthan gum, mixtures thereof, and the like.

- In preferred embodiments of the present invention, the aqueous pharmaceutical
- 30 formulation comprises about 0.03% to about 0.07% (w/w), more preferably about 0.04% to about 0.06% (w/w), and most preferably about 0.04% to about 0.05% (w/w) of fluticasone

propionate. In other preferred embodiments of the present invention, the aqueous pharmaceutical formulation comprises about 0.01% to about 0.50% (w/w), more preferably about 0.08% to about 0.40% (w/w), and most preferably about 0.10% to about 0.30% (w/w), of the antimicrobial preservative. In yet other preferred embodiments of the present invention, the aqueous pharmaceutical formulation comprises about 0.001% to about 0.050% (w/w), more preferably about 0.004% to about 0.030% (w/w), and most preferably about 0.005% to about 0.020% (w/w) of the surfactant. In preferred embodiments of the present invention, the aqueous pharmaceutical formulation comprises about 1.0% to about 10.0% (w/w), more preferably about 3.0% to about 7.0% (w/w), and most preferably about 4.0% to about 6.0% (w/w) of the tonicity agent. In yet other preferred embodiments of the present invention, the aqueous pharmaceutical formulation comprises about 0.5% to about 5.0% (w/w), more preferably about 1.0% to about 3.0% (w/w), and most preferably about 1.5% to about 2.0% (w/w) of the suspending agent.

The invention also comprises a method of administering a pharmaceutical formulation, such as the novel aqueous pharmaceutical formulation that set forth above, to produce a spray pattern having desired characteristics as measured by ovality of the spray pattern. Thus, in another aspect of the present invention there is provided a method of administering a pharmaceutical formulation, for example, the novel aqueous pharmaceutical formulation according to the invention comprising fluticasone, to a host in need of such treatment, comprising spraying the pharmaceutical formulation using a nasal pump spray device, wherein the average ovality ratio of the spray produced is between about 1.0 and about 1.7, more preferably between about 1.1 and about 1.5, even more preferably between about 1.2 and about 1.4, and most preferably between about 1.2 and about 1.3.

The invention also comprises a pharmaceutically acceptable nasal spray device including a swirl chamber dimensioned to produce a spray pattern having the desired average ovality ratio. This pharmaceutically acceptable nasal spray device may be used with the novel aqueous pharmaceutical formulation that set forth above or other pharmaceutical formulations. Therefore, in another aspect of the present invention there is provided a

pump spray device for a pharmaceutical formulation, the pump spray device comprising an actuator and a pump, wherein the improvement comprises: a swirl chamber insert and a central swirl chamber with at least three channels, each channel extending from the center of the swirl chamber to the outer diameter of the swirl chamber, wherein the ratio of the diameter of the center of the swirl chamber to the average width of the channels is between about 2.5 and about 3.3, more preferably between about 2.6 and about 3.1, even more preferably between about 2.7 and about 3.0, and most preferably between about 2.8 and about 3.0.

The invention also comprises fluticasone propionate having a defined surface area for appropriate local action. Thus, in another aspect of the present invention there is provided fluticasone propionate having a surface area (BET) in the range of about 7 m²/g to about 12 m²/g, more preferably in the range of about 8 m²/g to 10 m²/g, and most preferably in the range of about 9 m²/g to 10 m²/g.

15

Brief Description of the Figures

Figure 1 is a plan drawing of the pump portion of a conventional pump spray device used to illustrate the present invention with the various parts indicated.

Figure 2 is a plan drawing of an actuator portion of a conventional pump spray device used to illustrate the present invention with the various parts indicated.

Figure 3 is a diagram showing a central swirl chamber for use with the pump spray device according to the present invention with the various dimension measurements indicated.

25

Figure 4 shows the spray patterns obtained on a TLC plate for a pump spray device according to the present invention for single sprays of an aqueous fluticasone propionate formulation according to the present invention at various distances measured from the actuator to the TLC plate surface.

Definitions of Terms

In describing the invention the following terms as used herein have been defined to better describe the invention in all its aspects.

- 5 The term “swirl chamber insert” designates the part in nasal pump spray device that receives the metered dose of the pharmaceutical formulation from the pump portion of the nasal pump spray device and directs the metered dose into the central swirl chamber. An example of the swirl chamber insert is shown in Fig. 2.
- 10 The term “central swirl chamber” means the chamber at the top portion of the swirl chamber insert that receives the metered dose of the pharmaceutical formulation from the swirl chamber insert. The diameter of the central swirl chamber is the diameter d of the inner circular portion of the central swirl chamber, for example, illustrated in Fig. 3. The term “center of the swirl chamber” is the center of the swirl chamber, which is the location
- 15 of the orifice (not shown) through which the pharmaceutical formulation exits the nasal pump spray device.

- The terms “swirl chamber channels” or “channels” means the channels defined by the two channel walls and extending from the central swirl chamber to the outer diameter of the swirl chamber insert, which direct the metered dose of pharmaceutical formulation in a spray pattern external to the nasal pump spray device. The width of the channels is the width of the channels measured at a line perpendicular to the longer channel wall to the shorter channel wall nearest the central swirl chamber, illustrated as L1, L2, and L3 in Fig. 3.

- 25 The term “ovality ratio” as used herein is defined according to the FDA Draft Guidance and means the ratio of the widest (D_{max}) and shortest (D_{min}) diameters of a spray pattern following impaction on an appropriate target upon a single actuation of fluticasone propionate nasal product at a selected distance from the actuator to the target. The ovality
- 30 ratio provides information about the shape and density of the plume of Fluticasone propionate nasal product following actuation. The ovality ratio is determined at an

appropriate selected distance from the pump spray device actuator tip to the target (generally a TLC plate). Typical selected distances, for example, are about 0.5 cm to about 6.0 cm, about 0.75 cm to about 5.0 cm, about 1.0 cm to about 4.0 cm, about 1.5 cm to about 3.5 cm, and about 2.0 cm to about 3.0 cm.

5

The term "average ovality ratio" as used herein is the average ovality ratio produced from a pump spray device as determined from 3 or more consecutive sprays at 3 different distances between 0.5 to 6.0 cm.

10 The term "surface area (BET)" as used herein has the meaning defined in the U.S. Pharmacopoeia (USP 24) and is the specific surface area of a powder determined by physical adsorption of a gas on the surface of the fluticasone propionate solid and by measuring the amount of adsorbate gas corresponding to a single layer on the surface.

15 The term "average particle size" as used herein means a statistical mean value of the drug particle measured from at least 3 consecutive measurements.

As used herein, the term "drug" means any nasally-administered pharmaceutically effective compound, including anti-inflammatory drugs and systemically effective drugs.

20 The term "drug" is intended to include both presently available pharmaceutically active drugs used therapeutically and therapeutically effective drugs that will be developed in the future that can be nasally administered for local exposure or systemic absorption.

The term "anti-inflammatory drug" as used herein means any pharmaceutically effective
25 compound used in the treatment of any inflammatory disease and, in particular, the treatment of diseases related to seasonal and perennial allergic and nonallergic rhinitis. Such anti-inflammatory drugs include those which are listed within the Physicians' Desk Reference, 54th Edition (2000), incorporated herein by reference in its entirety, including steroids such as beclomethasone dipropionate, flunisolide, fluticasone, budesonide,
30 mometasone, and triamcinolone acetonide, particularly fluticasone. Other anti-inflammatory drugs include cromoglycates such as cromolyn sodium.

The terms "pharmaceutical formulation", "suspension formulation", and "aqueous pharmaceutical formulation" and the like are used herein to describe a pharmaceutically active drug or anti-inflammatory drug by itself or with a pharmaceutically acceptable carrier in flowable liquid or suspension form. Such formulations are preferably solutions and suspension, e.g., aqueous suspension and solutions, ethanolic suspension and solutions, aqueous/ethanolic suspension and solutions, saline solutions, and colloidal suspensions.

In general, the drugs and anti-inflammatory drugs are intended to encompass the free acids, free bases, salts, amines, and various hydrate forms including semi-hydrate forms of such drugs and anti-inflammatory drugs. When using the pump spray device according to the present invention or performing the method of administering a pharmaceutical formulation to a host in need of such treatment according to the present invention, it should be understood that the drugs and anti-inflammatory drugs are generally administered in the form of pharmaceutically acceptable formulations of such drugs which are formulated in combination with pharmaceutically acceptable excipient materials generally known to those skilled in the art and such pharmaceutical formulations consist essentially of the drug in combination with pharmaceutically acceptable excipients in a suitable carrier (e.g., water and/or ethanol). It should be noted, however, if a drug is a liquid without an excipient, the formulation may consist solely of a drug that has a sufficiently low viscosity.

Detailed Description of the Invention

One aspect of the present invention comprises a pharmaceutically acceptable nasal spray device including a swirl chamber dimensioned to produce a spray pattern having the desired average ovality ratio. Therefore, in another aspect of the present invention there is provided a pump spray device for a pharmaceutical formulation, the pump spray device comprising an actuator and a pump, wherein the improvement comprises: a swirl chamber insert having a central swirl chamber and at least three channels, each channel extending from the central swirl chamber to the outer diameter of the swirl chamber insert, wherein the ratio of the diameter of the central swirl chamber to the average width of the channels is between about 2.5 and about 3.3, more preferably between about 2.6 and about 3.1, even

more preferably between about 2.7 and about 3.0, and most preferably between about 2.8 and about 3.0.

Fig. 1 is a plan drawing of the pump portion of a pump spray device according to the present invention with the various parts indicated. The parts of the pump portion include stem 1, stem gasket 2, stem spring 3, ferrule 4, sealing gasket 5, piston 6, spring cap 7, pump body 8, return spring 9, spring support 10, floating gasket 11, and dip tube 12.

Fig. 2 is a plan drawing of an actuator portion of a conventional pump spray device used to illustrate according to the present invention with the various parts indicated. The actuator includes cap 13, swirl chamber insert 14, and actuator body 15. Actuator body 15 fits over stem 1 of the pump portion of a pump spray device to assemble the device for use.

Fig. 3 is a diagram showing a central swirl chamber according to the present invention for use with the pump spray device with the various dimension measurements indicated. In Fig. 3, symbol d indicates the diameter of the central swirl chamber and the symbols $L1$, $L2$, and $L3$ indicate the width of the channels. At the center of the swirl chamber (i.e., at the midpoint of d) there is the orifice (not shown) from which the pharmaceutical formulation emerges from the nasal pump spray device.

During use, the pump spray device functions as a conventional pump. Dip tube 12 is in contact with the liquid pharmaceutical formulation held in a container (not shown) that is sealed by ferrule 4. Generally, the actuator portion must be pressed down by the operator three or more times to prime the pump at the initial operation of the pump spray device. Before pressing down on actuator body 15, cap 13 is removed. At rest, the pump spray device is sealed at stem gasket 2 and sealing gasket 5. When the pump spray device is pressurized by pressing down on actuator body 15, floating gasket 11 is pressed against the base to form a tight seal, which leads to an increase in pressure in the chamber within pump body 8. As the pharmaceutical formulation within pump body 8 cannot be compressed, piston 6 is blocked in its downward movement. Continuing movement of actuator body 15 downward forces stem 1 downward until the orifice near the base of stem

- 1 is exposed to the pressurized chamber within pump body 8 and the pharmaceutical formulation travels up the central passage within stem 1 through swirl chamber insert 14 to the central swirl chamber according to the present invention at the far end (i.e., farthest from stem 1) of swirl chamber insert 14. The pharmaceutical formulation emerges from swirl chamber insert 14 into the central swirl chamber and is directed along the channels and propelled through the orifice of the central swirl chamber (i.e., at midpoint d) to produce a spray pattern of a desired ovality. At this point spraying is completed and stem spring 3 returns piston 6 to its original position and return spring 9 pushes all moving parts to their original position. While the pump device is returned to its original position, the orifice near the base of stem 1 is isolated from the chamber within pump body 8, creating a vacuum, raising floating gasket 11 and allowing the liquid pharmaceutical formulation held in a container to travel up dip tube 12, repriming the pump spray device with a metered dose of the liquid pharmaceutical formulation.
- 15 All of the parts of the pump spray device are made from pharmaceutically acceptable materials appropriate for the pharmaceutical formulation used therein.

To the extent that a pump spray device does not have a central swirl chamber according to the present invention, that is, a central swirl chamber and at least three channels, each channel extending from the central swirl chamber to the outer diameter of the swirl chamber insert, wherein the ratio of the diameter of the central swirl chamber to the average width of the channels is between about 2.5 and about 3.3, it is deemed a "conventional" pump spray device herein, although it may or may not be in the prior art. Thus, the pump spray device of Figs. 1 and 2 is used for illustrative purposes only and equivalent pump spray devices known to those of skill in the art, although somewhat different in form or operation from the one described in Figs. 1 and 2, may incorporate the central swirl chamber or be modified to incorporate the central swirl chamber according to the present invention according to the present invention, as would be apparent to those of skill in the art, and is intended to be embraced within the present invention.

30

Typical dimensions for the central swirl chamber and channel widths of the swirl chamber insert are shown in Table I, where Pump A is outside the scope of the present invention and included for comparison purposes and Pumps B, C, and D are pump spray devices according to the present invention.

5

TABLE I						
Pump	Diameter of Central Swirl Chamber (mm)	Channel Width (mm)			Average Channel Width (mm)	Ratio of D/L _{avg}
	d	L1	L2	L3	L _{avg}	
A	1.01	0.32	0.29	0.27	0.293	3.443
B	1.07	0.38	0.38	0.38	0.380	2.816
C	1.02	0.36	0.35	0.36	0.357	2.860
D	1.01	0.35	0.38	0.35	0.360	2.806

Ovality Measurement Protocol

Spray pattern characterizes the spray following impaction on an appropriate target, for example, a thin-layer chromatographic (TLC) plate. Spray pattern is generally determined on a single actuation at several, preferably 3 or more, appropriate distances, e.g., about 0.5 cm to about 6.0 cm, about 0.75 cm to about 5.0 cm, about 1.0 cm to about 4.0 cm, about 1.5 cm to about 3.5 cm, and about 2.0 cm to about 3.0 cm, from the actuator to the target. The visualization technique used is specific for fluticasone propionate: the spray pattern is viewed under 254 nm UV light. Clear, legible photographs of photocopies of the spray pattern are obtained. An example of such spray pattern visualization obtained for Pump D of Table I for single sprays at 0.5 cm, 1.0 cm, 1.5 cm, 2.0 cm, 2.5 cm, 3.0 cm, 3.5 cm, 4.0 cm, and 4.5 cm is shown in Fig. 4. The widest (D_{\max}) and shortest (D_{\min}) diameters are of such sprays are measured. The ovality ratio (D_{\max}/D_{\min}) is calculated for each spray. The average ovality ratio values of approaching 1.0 represents a circular pattern, whereas the ovality ratio of substantially greater than 1.5 represent an elliptical or irregular pattern.

Ovality Measurement Experiments

The fluticasone lots were prepared according to the invention and tested for the spray pattern according to the above protocol.

- 5 Table II show fluticasone propionate lot numbers, number of bottles tested, and spray pattern results of pump spray devices according to the instant invention.

TABLE II				
Lot Number	Number of Bottles Tested	Number of Sprays per Bottle	Average Ovality Ratio	Range Ovality Ratio (Min-Max)
009014C	10	3	1.25	(1.06-1.57)
009015C	10	3	1.22	(1.03-1.54)
009016C	10	3	1.20	(1.05-1.58)
009014D	10	3	1.16	(1.00-1.36)
009015D	10	3	1.20	(1.05-1.66)
009016D	10	3	1.15	(1.05-1.28)

We Claim:

1. An aqueous pharmaceutical formulation suitable for use in a pump spray device, comprising:

- (a) fluticasone propionate;
- (b) an antimicrobial preservative;
- (c) a surfactant;
- (d) a tonicity agent; and
- (e) a suspending agent.

2. The aqueous pharmaceutical formulation according to claim 1, wherein the antimicrobial preservative is selected from the group consisting of: benzalkonium chloride, methylparaben, sodium benzoate, benzoic acid, phenyl ethyl alcohol, and mixtures thereof.

3. The aqueous pharmaceutical formulation according to claim 1, wherein the surfactant is selected from the group consisting of: Polysorbate 80 NF, polyoxyethylene 20 sorbitan monolaurate, polyoxyethylene (4) sorbitan monolaurate, polyoxyethylene 20 sorbitan monopalmitate, polyoxyethylene 20 sorbitan monostearate, polyoxyethylene (4) sorbitan monostearate, polyoxyethylene 20 sorbitan tristearate, polyoxyethylene (5) sorbitan monooleate, polyoxyethylene 20 sorbitan trioleate, polyoxyethylene 20 sorbitan monoisostearate, sorbitan monooleate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan trilaurate, sorbitan trioleate, sorbitan tristearate, and mixtures thereof.

4. The aqueous pharmaceutical formulation according to claim 1, wherein the tonicity agent is selected from the group consisting of: dextrose, lactose, sodium chloride, and mixtures thereof.

5. The aqueous pharmaceutical formulation according to claim 1, wherein the suspending agent is selected from the group consisting of: microcrystalline cellulose,

carboxymethylcellulose sodium NF, polyacrylic acid, magnesium aluminum silicate, xanthan gum, and mixtures thereof.

6. The aqueous pharmaceutical formulation according to claim 1, comprising:
 - (a) about 0.03% to about 0.07% (w/w) of fluticasone propionate;
 - (b) about 0.05% to about 0.50% (w/w) of the antimicrobial preservative;
 - (c) about 0.001% to about 0.050% (w/w) of the surfactant;
 - (d) about 1.0% to about 10.0% (w/w) of the tonicity agent; and
 - (e) about 0.5% to about 5.0% (w/w) of a suspending agent.
7. The aqueous pharmaceutical formulation according to claim 1, comprising:
 - (a) about 0.04% to about 0.06% (w/w) of fluticasone propionate;
 - (b) about 0.08% to about 0.40% (w/w) of the antimicrobial preservative;
 - (c) about 0.004% to about 0.030% (w/w) of the surfactant;
 - (d) about 3.0% to about 7.0% (w/w) of the tonicity agent; and
 - (e) about 1.0% to about 3.0% (w/w) of a suspending agent.
8. The aqueous pharmaceutical formulation according to claim 1, comprising:
 - (a) about 0.04% to about 0.06% (w/w) of fluticasone propionate;
 - (b) about 0.01% to about 0.40% (w/w) of phenylethyl alcohol and benzalkonium chloride;
 - (c) about 0.004% to about 0.030% (w/w) of Polysorbate 80 NF;
 - (d) about 3.0% to about 7.0% (w/w) of dextrose; and
 - (e) about 1.0% to about 3.0% (w/w) of microcrystalline cellulose and carboxymethylcellulose sodium NF.
9. A method of administering a pharmaceutical formulation to a host in need of such treatment, comprising spraying the aqueous pharmaceutical formulation according to claim 1 using a nasal pump spray device, wherein the average ovality ratio of the spray produced is between about 1.0 and about 1.7.

10. The method of claim 9, wherein the average ovality ratio of the spray produced is between about 1.1 and about 1.5.

11. The method according to claim 10, wherein the average ovality ratio of the spray produced is between about 1.1 and about 1.3.

12. In a pump spray device for a pharmaceutical formulation, the pump spray device comprising an actuator and a pump, wherein the improvement comprises:

a swirl chamber insert with a central swirl chamber and at least three channels, each channel extending from the central swirl chamber to the outer diameter of the swirl chamber insert,

wherein the ratio of the diameter of the central swirl chamber to the average width of the channels is between about 2.5 and about 3.3.

13. The pump spray device of claim 12, wherein the ratio of the diameter of the central swirl chamber to the average width of the channels is between about 2.6 and about 3.1.

14. The pump spray device of claim 13, wherein the ratio of the diameter of the central swirl chamber to the average width of the channels is between about 2.7 and about 3.0.

15. The pump spray device of claim 14, wherein the ratio of the diameter of the central swirl chamber to the average width of the channels is between about 2.8 and about 3.0.

16. Fluticasone propionate having a surface area (BET) in the range of about 7 m²/g to about 12 m²/g.

17. Fluticasone propionate according to claim 16, wherein the surface area (BET) is in the range of about 8 m²/g to 10 m²/g.

18. Fluticasone propionate according to claim 17, wherein the surface area (BET) is in the range of about 9 m²/g to 10 m²/g.




FIG. 1




FIG. 2





FIG. 3



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number
WO 02/053186 A3

- (51) International Patent Classification⁷: A61K 9/72, 31/56 (74) Agents: RAYMOND, Robert, P. et al.; Boehringer Ingelheim Corp., 900 Ridgebury Road, Ridgefield, CT 06877 (US).
- (21) International Application Number: PCT/US02/00104
- (22) International Filing Date: 4 January 2002 (04.01.2002) (81) Designated States (*national*): CA, JP, MX.
- (25) Filing Language: English (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).
- (26) Publication Language: English
- (30) Priority Data: 09/754,777 5 January 2001 (05.01.2001) US Published: — with international search report
- (71) Applicant: ROXANE LABORATORIES, INC. [US/US]; 1809 Wilson Road, COLUMBUS, OH 43228 (US). (88) Date of publication of the international search report: 22 May 2003
- (72) Inventors: DEDHIYA, Mahendra; 6360 Twonotch Court, Dublin, OH 43016 (US). ECONOMOU, Julia; 2574 Cowall Drive, Hilliard, OH 43026 (US). For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/053186 A3

(54) Title: FLUTICASONE SUSPENSION FORMULATION, SPRAY PATTERN METHOD, AND NASAL SPRAY APPARATUS

(57) Abstract: An aqueous pharmaceutical formulation suitable for use in a pump spray device, comprising (a) fluticasone propionate, (b) an antimicrobial preservative, (c) a surfactant, (d) a tonicity agent, and (e) a suspending agent; methods for using the aqueous pharmaceutical formulation, and suitable pump spray devices.

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT/US 02/00104

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/72 A61K31/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 01 78745 A (GLAXO GROUP LTD ; ROCHE TREVOR CHARLES (GB); GAVIN BRIAN CHARLES (I) 25 October 2001 (2001-10-25) page 6, line 22 - page 7, line 17 example 7	1-8
X	EP 0 709 099 A (SENJU PHARMA CO) 1 May 1996 (1996-05-01) page 3, line 15 - line 49	1-8
A	WO 96 19968 A (GLAXO GROUP LTD ; GREEN ALEXANDER PETER (GB)) 4 July 1996 (1996-07-04) examples	1-8

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the International filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the International filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

28 November 2002

Date of mailing of the international search report

26. 02. 03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo.nl,
Fax (+31-70) 340-3018

Authorized officer

Giménez Miralles, J

INTERNATIONAL SEARCH REPORT

In onal application No.
PCT/US 02/00104

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-8

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-8

Aqueous fluticasone propionate formulation comprising, besides the active agent, an antimicrobial preservative, a surfactant, a tonicity agent, and a suspending agent.

2. Claims: 9-15

Pump spray device for delivering a pharmaceutical formulation with a particular spray pattern; and method of nasal administration of an aqueous pharmaceutical formulation according to claim 1 by using said (nasal) pump spray device.

3. Claims: 16-18

Fluticasone propionate (microparticles) having a specific surface area.

INTERNATIONAL SEARCH REPORT

Intern

Application No

PCT/US 02/00104

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0178745	A	25-10-2001	AU 4672301 A WO 0178745 A1	30-10-2001 25-10-2001
EP 0709099	A	01-05-1996	AU 3290595 A CA 2159288 A1 EP 0709099 A2 JP 8151332 A	18-04-1996 29-03-1996 01-05-1996 11-06-1996
WO 9619968	A	04-07-1996	AT 195249 T AU 4346996 A DE 69518334 D1 DE 69518334 T2 DK 799024 T3 WO 9619968 A1 EP 0799024 A1 ES 2150022 T3 GR 3034477 T3 JP 10511376 T PT 799024 T US 5955439 A	15-08-2000 19-07-1996 14-09-2000 25-01-2001 08-01-2001 04-07-1996 08-10-1997 16-11-2000 29-12-2000 04-11-1998 29-12-2000 21-09-1999